Literature DB >> 21103537

Pressure-amorphized cubic structure II clathrate hydrate: crystallization in slow motion.

Marion Bauer1, Daniel M Többens, Erwin Mayer, Thomas Loerting.   

Abstract

A range of techniques has so far been employed for producing amorphous aqueous solutions. In case of aqueous tetrahydrofuran (THF) this comprises hyperquenching of liquid droplets, vapour co-deposition and pressure-induced amorphization of the crystalline cubic structure II clathrate. All of these samples are thermally labile and crystallize at temperatures above 110 K. We here outline a variant of the pressure-amorphization protocol developed by Suzuki [Phys. Rev. B, 2004, 70, 172108], which results in a highly crystallization resistant amorphous THF hydrate. The hydrate produced according to our protocol (annealing to 180 K at 1.8 GPa rather than to 150 K at 1.5 GPa) does not transform to the cubic structure II THF clathrate even at 150 K. We track the reason for this higher stability to the presence of crystalline remnants when following the Suzuki protocol, which are removed when using our protocol involving higher pressures and an annealing step. These crystalline remnants later serve as crystallization seeds lowering the thermal stability of the amorphous sample. Our protocol thus makes a purely amorphous THF hydrate available to the research community. We use powder X-ray diffraction to study the process of nucleation and slow crystal growth in the temperature range 160-200 K and find that the local cage structure and periodicity of the fully crystalline hydrate develops even at the earliest stages of crystallization, when the "clathrate crystal" has a size of about two unit cells.

Entities:  

Year:  2010        PMID: 21103537     DOI: 10.1039/c0cp01351j

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  1 in total

1.  Structural investigation of three distinct amorphous forms of Ar hydrate.

Authors:  Paulo H B Brant Carvalho; Pedro Ivo R Moraes; Alexandre A Leitão; Ove Andersson; Chris A Tulk; Jamie Molaison; Alexander P Lyubartsev; Ulrich Häussermann
Journal:  RSC Adv       Date:  2021-09-15       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.